Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Non-Current Receivables (2023 - 2024)

Historic Non-Current Receivables for Gyre Therapeutics (GYRE) over the last 2 years, with Q4 2024 value amounting to $5.0 million.

  • Gyre Therapeutics' Non-Current Receivables rose 588.73% to $5.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.0 million, marking a year-over-year increase of 588.73%. This contributed to the annual value of $5.0 million for FY2024, which is 588.73% up from last year.
  • Per Gyre Therapeutics' latest filing, its Non-Current Receivables stood at $5.0 million for Q4 2024, which was up 588.73% from $4.9 million recorded in Q3 2024.
  • Gyre Therapeutics' Non-Current Receivables' 5-year high stood at $5.0 million during Q4 2024, with a 5-year trough of $4.6 million in Q1 2023.